ArticleFrontiers in neurology2025
Trends in prescription of new antiseizure medications in a single center in Latin America: evidence of clinical practice.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epilepsy affects approximately 70 million people globally, with a prevalence in Mexico of 10.8 to 20 cases per thousand. Antiseizure Medications (ASM) are the first line of treatment for people with epilepsy (PWE), aiming to achieve early seizure control while minimizing adverse effects that could impact quality of life. Materials and methods: This retrospective cohort study analyzed data from 2020 to 2024 collected from medical records, clinical histories, and electronic systems, using REDCAP Results: Of 1,192 prescriptions, third-generation ASMs accounted for the majority (53.7%), led by levetiracetam (24.1%), lamotrigine (14%), and lacosamide (6%). Second-generation ASMs comprised 42.4%, including valproate (21.5%), carbamazepine (11.3%), and clonazepam (5.5%). First-generation ASMs were less frequently prescribed (3.9%), primarily phenytoin (2.3%), primidone (1.0%), and phenobarbital (0.3%). Third-generation ASMs were the most prescribed for focal seizures (38.6%), generalized seizures (13.3%), and seizures of unknown (1.9%) or unclassified types (2.1%). Discussion: Compared to a 2012 study in the same population, which showed second-generation ASM as dominant, this study highlights a significant shift toward third-generation ASM, now representing over half of prescriptions. While valproate and carbamazepine remain versatile second-generation options, newer ASMs, such as levetiracetam, are increasingly favored. Conclusion: These findings demonstrate a preference for second- and third-generation ASMs in tertiary hospitals in Latin America, which is concordant with global trends. First-generation ASMs are still prescribed but at lower rates. These results provide insights into changing prescription practices and access to newer medications, informing future research and hospital policies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.